Inhaler testing specialist Copley Scientific has announced the launch of its new Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX. The company launched Version 1 of Inhalytix+, a subscription-based cascade impactor software package, in August 2025. The TPK 200iX critical flow controller replaces the TPK 100iX model.
Copley Head of Business Development Paul Martin commented, “The inhaler testing laboratory is changing. Customers need greater confidence in their results and the workflows delivering them. Stronger method control, fewer sources of variability and rigorous data management are becoming essential to progress efficiently and demonstrate the robust consistency and integrity that regulators are looking for. Inhalytix+ v2.0 and the TPK 200iX enable implementation of the connected inhaler testing workflows needed to realize these goals and reflect a broader direction of travel towards more consistent testing performance . . . . This launch reflects where inhaler testing is heading: towards more connected workflows that are traceable, transferable, and scalable.”
Previously this year, Copley has launched a new Inhaled Dissolution Apparatus (IDA) for dissolution testing of OINDPs and the SRS 100i automated sample recovery system for use with delivered dose uniformity and APSD testing systems.
Read the Copley Scientific press release
